Forest/Lipha Campral
Executive Summary
FDA approves Campral (acamprosate) July 29 for the treatment of "alcohol dependent individuals seeking to continue to remain alcohol-free after they have stopped drinking." Campral should be used as one part of a comprehensive alcoholism management program that includes "psychosocial support," FDA says in a July 29 "Talk Paper." Forest will launch the drug in the U.S. near the end of the year...